in8bio.com (INAB) Price-to-Projected Revenue Ratio

Corporate company logo of IN8bio Inc (INAB)

IN8bio, Inc. (INAB) integrates gamma-delta T-cell modification into bone transplants for the targeted destruction of tumors. The forward price-to-sales ratio demonstrates valuation dynamics, where characterizes this valuation parameter. Growth is based on alliances with oncology centers and the acquisition of patents. Business security is ensured by US localization and international protection of medical developments.

IN8bio (INAB): Forward P/S Multiple from 07/04/2022 to 11/13/2026

IN8bio Inc (INAB) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Price IN8bio|INAB - Analyst Median Target
- market capitalization details:
Market Value IN8bio Inc|INAB - Business Value
- book value of equity indicators:
Accounting Value of a Share IN8bio|INAB - Book Capitalization|Market Value to Book Value Ratio in8bio.com|INAB - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Capital Coefficient IN8bio, Inc.|INAB - Long-Term Debt to Equity|Current Liabilities to Capital IN8bio, Inc.|INAB - Company Total Debt|Debt to Net Assets Ratio IN8bio Inc|INAB - Company Long-Term Debts|Short-Term Debt Volume IN8bio|Immediate Liquidity Ratio in8bio.com
- net income and valuation ratios data:
INAB - Net Profit|Future Profit IN8bio, Inc.|INAB - Price to Earnings Ratio|Market Cap to Projected Earnings IN8bio, Inc|INAB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio IN8bio Inc|INAB - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months IN8bio|INAB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth in8bio.com|INAB - Earnings growth in current year|Net earnings per share growth forecast for next year IN8bio, Inc.
- total revenue and sales volume data:
INAB - Revenue and Sales Volume|Company Future Sales Volume IN8bio|INAB - P/S Multiple|Forward P/S Multiple IN8bio Inc
Analysis of all company metrics:INAB, IN8bio
Brand item of IN8bio Inc.

Forward P/S measures the market value of a business relative to projected revenue, reflecting market expectations for future sales growth rates. Analyzing the expected P/S valuation helps identify speculative overheating, which is critical for IN8bio, Inc. (INAB), as the absence of stable cash flows makes the company's capitalization dependent on the success of clinical trials and external financing.

Competitors of IN8bio, Inc.

Forward P/S Multiple TGTX (TG Therapeutics)|Market Cap to Expected Sales Ratio Arcellx Inc (ACLX)|IRON - Price-to-Projected Revenue Ratio|SNDX (Syndax Corp) - Market Cap to Projected Revenue|Forward Price to Sales Kura Oncology, Inc. KURA|adctherapeutics.com (ADCT) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Foghorn Therapeutics, Inc.|Forward P/S Multiple Vor Biopharma, Inc.|NKTX (Nkarta, Inc.) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio COEP (coeptistx.com)|ATNM: Market Cap to Future Revenue Ratio|ESLA - Forward Price-to-Revenue Multiple|Forward Price to Sales CASI Pharmaceuticals, Inc (CASI)|MRKR - Forward P/S Multiple|eternatx.com - Market Cap to Expected Sales Ratio|GTBP (GT Biopharma Corporation) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue Aptose Biosciences Inc (APTO)|Forward P/S Multiple biopathholdings.com|Forward Price-to-Revenue Multiple MEIP (MEI Pharma)|Forward Price-to-Revenue Multiple vincerx.com VINC